Moreover, despite the increase in erythropoietic activity and GDF15 levels, it was hypothesized that the normal levels of hepcidin measured in MPN patients could be a defense mechanism to reduce iron utilization in order to prevent erythropoietic activity from increasing (17). The gene discussed is HAMP; the disease is myeloproliferative disorder.